{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:22:41Z","timestamp":1784622161280,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated cirrhosis and HBV-associated carcinoma are high and increasing. This study was designed to evaluate serum lipid metabolite changes that are associated with the progression from CHB to HBV-associated cirrhosis and ultimately to HBV-associated HCC. A targeted metabolomic assay was performed in fasting sera from 136 CHB patients, 104 HBV-associated cirrhosis, and 95 HBV-associated HCC using ultra-performance liquid chromatography triple quadrupole mass spectrometry. A total of 140 metabolites were identified. Clear separations between each two groups were obtained using the partial least squares discriminate analysis of 9 lipid metabolites. Progressively lower levels of long-chain lysophosphatidylcholines (lysoPC a C18:2, lysoPC a C20:3, lysoPC a C20:4) were observed from CHB to cirrhosis to carcinoma; lower levels of lysoPC a C20:4 were found in patients with higher model for end-stage liver disease in the same disease group; and lysoPC a C20:3 levels were lower in Child-Pugh Class C than in Class A and Class B in HBV-associated cirrhosis and HBV-associated HCC groups. The octadecadienyl carnitine level was higher in HBV-associated cirrhosis group than in other two groups. Serum levels of selected long-chain lysoPCs are promising markers for the progression of HBV-associated liver diseases.<\/jats:p>","DOI":"10.1038\/srep42710","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T11:36:30Z","timestamp":1487158590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Panee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"BFsrep42710_CR1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2013.06.029","volume":"59","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. et al. Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol 59, 1073\u20131080 (2013).","journal-title":"J Hepatol"},{"key":"BFsrep42710_CR2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(70)91737-X","volume":"1","author":"S Sherlock","year":"1970","unstructured":"Sherlock, S., Fox, R. A., Niazi, S. P. & Scheuer, P. J. Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet 1, 1243\u20131247 (1970).","journal-title":"Lancet"},{"key":"BFsrep42710_CR3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.aca.2012.07.013","volume":"743","author":"HW Ressom","year":"2012","unstructured":"Ressom, H. W. et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 743, 90\u2013100 (2012).","journal-title":"Anal Chim Acta"},{"key":"BFsrep42710_CR4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02544628","volume":"8","author":"SH Chen","year":"1973","unstructured":"Chen, S. H. & Lombardi, B. Activity of fatty acyl CoA-lysophospholipid acyltransferases in liver microsomes of rats fed a choline-deficient diet. Lipids 8, 163\u2013165 (1973).","journal-title":"Lipids"},{"key":"BFsrep42710_CR5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jss.2012.10.037","volume":"182","author":"NJ Skill","year":"2013","unstructured":"Skill, N. J. et al. Lysophospholipid variants in hepatocellular carcinoma. J Surg Res 182, 241\u2013249 (2013).","journal-title":"J Surg Res"},{"key":"BFsrep42710_CR6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.tibtech.2005.08.005","volume":"23","author":"J Nielsen","year":"2005","unstructured":"Nielsen, J. & Oliver, S. The next wave in metabolome analysis. Trends Biotechnol 23, 544\u2013546 (2005).","journal-title":"Trends Biotechnol"},{"key":"BFsrep42710_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.copbio.2010.09.008","volume":"22","author":"M Heinemann","year":"2011","unstructured":"Heinemann, M. & Zenobi, R. Single cell metabolomics. Curr Opin Biotechnol 22, 26\u201331 (2011).","journal-title":"Curr Opin Biotechnol"},{"key":"BFsrep42710_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrd728","volume":"1","author":"JK Nicholson","year":"2002","unstructured":"Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1, 153\u2013161 (2002).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep42710_CR9","first-page":"4123","volume":"19","author":"J Liang","year":"2015","unstructured":"Liang, J., Han, T., Gao, Y. T., Jing, L. & Ma, Z. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci 19, 4123\u20134129 (2015).","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"BFsrep42710_CR10","doi-asserted-by":"crossref","first-page":"e78430","DOI":"10.1371\/journal.pone.0078430","volume":"8","author":"C Then","year":"2013","unstructured":"Then, C. et al. Plasma metabolomics reveal alterations of sphingo- and glycerophospholipid levels in non-diabetic carriers of the transcription factor 7-like 2 polymorphism rs7903146. PLoS One 8, e78430 (2013).","journal-title":"PLoS One"},{"key":"BFsrep42710_CR11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cmet.2009.02.002","volume":"9","author":"CB Newgard","year":"2009","unstructured":"Newgard, C. B. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9, 311\u2013326 (2009).","journal-title":"Cell Metab"},{"key":"BFsrep42710_CR12","doi-asserted-by":"crossref","first-page":"e10883","DOI":"10.1371\/journal.pone.0010883","volume":"5","author":"WE Gall","year":"2010","unstructured":"Gall, W. E. et al. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 5, e10883 (2010).","journal-title":"PLoS One"},{"key":"BFsrep42710_CR13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1039\/b820224a","volume":"5","author":"P Yin","year":"2009","unstructured":"Yin, P. et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 5, 868\u2013876 (2009).","journal-title":"Mol Biosyst"},{"key":"BFsrep42710_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.aca.2009.03.039","volume":"650","author":"J Chen","year":"2009","unstructured":"Chen, J. et al. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 650, 3\u20139 (2009).","journal-title":"Anal Chim Acta"},{"key":"BFsrep42710_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.aca.2011.02.038","volume":"691","author":"H Cao","year":"2011","unstructured":"Cao, H. et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 691, 68\u201375 (2011).","journal-title":"Anal Chim Acta"},{"key":"BFsrep42710_CR16","doi-asserted-by":"crossref","unstructured":"Chen, T. et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 10, M110 004945 (2011).","DOI":"10.1074\/mcp.A110.004945"},{"key":"BFsrep42710_CR17","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1158\/0008-5472.CAN-11-0885","volume":"71","author":"AD Patterson","year":"2011","unstructured":"Patterson, A. D. et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 71, 6590\u20136600 (2011).","journal-title":"Cancer Res"},{"key":"BFsrep42710_CR18","doi-asserted-by":"crossref","unstructured":"Tan, Y. et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics 11, M111 010694 (2012).","DOI":"10.1074\/mcp.M111.010694"},{"key":"BFsrep42710_CR19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1053\/j.gastro.2013.01.054","volume":"144","author":"A Budhu","year":"2013","unstructured":"Budhu, A. et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144, 1066\u20131075 e1061 (2013).","journal-title":"Gastroenterology"},{"key":"BFsrep42710_CR20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/pr2009252","volume":"11","author":"B Wang","year":"2012","unstructured":"Wang, B. et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 11, 1217\u20131227 (2012).","journal-title":"J Proteome Res"},{"key":"BFsrep42710_CR21","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1021\/pr300683a","volume":"11","author":"L Zhou","year":"2012","unstructured":"Zhou, L. et al. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. J Proteome Res 11, 5433\u20135442 (2012).","journal-title":"J Proteome Res"},{"key":"BFsrep42710_CR22","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/ijms15022991","volume":"15","author":"K Eisinger","year":"2014","unstructured":"Eisinger, K. et al. Lipidomic analysis of serum from high fat diet induced obese mice. Int J Mol Sci 15, 2991\u20133002 (2014).","journal-title":"Int J Mol Sci"},{"key":"BFsrep42710_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prostaglandins.2016.06.001","volume":"124","author":"S Krautbauer","year":"2016","unstructured":"Krautbauer, S., Eisinger, K., Wiest, R., Liebisch, G. & Buechler, C. Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis. Prostaglandins Other Lipid Mediat 124, 27\u201333 (2016).","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"BFsrep42710_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","volume":"8","author":"CN Serhan","year":"2008","unstructured":"Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349\u2013361 (2008).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep42710_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","volume":"688","author":"CR Gault","year":"2010","unstructured":"Gault, C. R., Obeid, L. M. & Hannun, Y. A. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688, 1\u201323 (2010).","journal-title":"Adv Exp Med Biol"},{"key":"BFsrep42710_CR26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0022-2275(20)42638-0","volume":"31","author":"O Satoh","year":"1990","unstructured":"Satoh, O., Umeda, M., Imai, H., Tunoo, H. & Inoue, K. Lipid composition of hepatitis B virus surface antigen particles and the particle-producing human hepatoma cell lines. J Lipid Res 31, 1293\u20131300 (1990).","journal-title":"J Lipid Res"},{"key":"BFsrep42710_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj3370023","volume":"337","author":"L Tessitore","year":"1999","unstructured":"Tessitore, L., Dianzani, I., Cui, Z. & Vance, D. E. Diminished expression of phosphatidylethanolamine N-methyltransferase 2 during hepatocarcinogenesis. Biochem J 337 (Pt 1), 23\u201327 (1999).","journal-title":"Biochem J"},{"key":"BFsrep42710_CR28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.bbadis.2015.09.006","volume":"1852","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Lack of phosphatidylethanolamine N-methyltransferase alters hepatic phospholipid composition and induces endoplasmic reticulum stress. Biochim Biophys Acta 1852, 2689\u20132699 (2015).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep42710_CR29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1042\/bj3120939","volume":"312","author":"Z Cui","year":"1995","unstructured":"Cui, Z., Houweling, M. & Vance, D. E. Expression of phosphatidylethanolamine N-methyltransferase-2 in McArdle-RH7777 hepatoma cells inhibits the CDP-choline pathway for phosphatidylcholine biosynthesis via decreased gene expression of CTP:phosphocholine cytidylyltransferase. Biochem J 312 (Pt 3), 939\u2013945 (1995).","journal-title":"Biochem J"},{"key":"BFsrep42710_CR30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2013.02.030","volume":"59","author":"Y Morita","year":"2013","unstructured":"Morita, Y. et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol 59, 292\u2013299 (2013).","journal-title":"J Hepatol"},{"key":"BFsrep42710_CR31","doi-asserted-by":"crossref","first-page":"e103532","DOI":"10.1371\/journal.pone.0103532","volume":"9","author":"T Pleli","year":"2014","unstructured":"Pleli, T. et al. Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis\u2013a prospective cohort study. PLoS One 9, e103532 (2014).","journal-title":"PLoS One"},{"key":"BFsrep42710_CR32","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cca.2012.07.014","volume":"413","author":"H Ikeda","year":"2012","unstructured":"Ikeda, H. & Yatomi, Y. Autotaxin in liver fibrosis. Clin Chim Acta 413, 1817\u20131821 (2012).","journal-title":"Clin Chim Acta"},{"key":"BFsrep42710_CR33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1021\/pr050364w","volume":"5","author":"J Yang","year":"2006","unstructured":"Yang, J. et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J Proteome Res 5, 554\u2013561 (2006).","journal-title":"J Proteome Res"},{"key":"BFsrep42710_CR34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1349-7006.2009.01086.x","volume":"100","author":"H Gao","year":"2009","unstructured":"Gao, H. et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci 100, 782\u2013785 (2009).","journal-title":"Cancer Sci"},{"key":"BFsrep42710_CR35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11306-011-0329-9","volume":"8","author":"E Gonzalez","year":"2012","unstructured":"Gonzalez, E. et al. Serum UPLC-MS\/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 8, 997\u20131011 (2012).","journal-title":"Metabolomics"},{"key":"BFsrep42710_CR36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1194\/jlr.M200401-JLR200","volume":"44","author":"W Drobnik","year":"2003","unstructured":"Drobnik, W. et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 44, 754\u2013761 (2003).","journal-title":"J Lipid Res"},{"key":"BFsrep42710_CR37","doi-asserted-by":"crossref","unstructured":"Zuckerman, V. et al. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells. Oncotarget (2015).","DOI":"10.18632\/oncotarget.6696"},{"key":"BFsrep42710_CR38","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1038\/srep08421","volume":"5","author":"H Li","year":"2015","unstructured":"Li, H. et al. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci Rep 5, 8421 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep42710_CR39","doi-asserted-by":"crossref","first-page":"e103955","DOI":"10.1371\/journal.pone.0103955","volume":"9","author":"ES Park","year":"2014","unstructured":"Park, E. S. et al. Phosphatidylcholine alteration identified using MALDI imaging MS in HBV-infected mouse livers and virus-mediated regeneration defects. PLoS One 9, e103955 (2014).","journal-title":"PLoS One"},{"key":"BFsrep42710_CR40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/GIM.0b013e3181614289","volume":"10","author":"P Rinaldo","year":"2008","unstructured":"Rinaldo, P., Cowan, T. M. & Matern, D. Acylcarnitine profile analysis. Genet Med 10, 151\u2013156 (2008).","journal-title":"Genet Med"},{"key":"BFsrep42710_CR41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/bmc.2995","volume":"27","author":"FR Mansour","year":"2013","unstructured":"Mansour, F. R., Wei, W. & Danielson, N. D. Separation of carnitine and acylcarnitines in biological samples: a review. Biomed Chromatogr 27, 1339\u20131353 (2013).","journal-title":"Biomed Chromatogr"},{"key":"BFsrep42710_CR42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00216-002-1654-7","volume":"375","author":"M Moder","year":"2003","unstructured":"Moder, M., Kiessling, A., Loster, H. & Bruggemann, L. The pattern of urinary acylcarnitines determined by electrospray mass spectrometry: a new tool in the diagnosis of diabetes mellitus. Anal Bioanal Chem 375, 200\u2013210 (2003).","journal-title":"Anal Bioanal Chem"},{"key":"BFsrep42710_CR43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11306-011-0345-9","volume":"8","author":"DK Thompson","year":"2012","unstructured":"Thompson, D. K. et al. Daily Variation of Serum Acylcarnitines and Amino Acids. Metabolomics 8, 556\u2013565 (2012).","journal-title":"Metabolomics"},{"key":"BFsrep42710_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00216-012-5782-4","volume":"403","author":"L Zhou","year":"2012","unstructured":"Zhou, L. et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 403, 203\u2013213 (2012).","journal-title":"Anal Bioanal Chem"},{"key":"BFsrep42710_CR45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7869\/tg.158","volume":"35","author":"J Ramachandran","year":"2014","unstructured":"Ramachandran, J., Sajith, K. G., Priya, S., Dutta, A. K. & Balasubramanian, K. A. Serum cholinesterase is an excellent biomarker of liver cirrhosis. Trop Gastroenterol 35, 15\u201320 (2014).","journal-title":"Trop Gastroenterol"},{"key":"BFsrep42710_CR46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0006-291X(03)00295-X","volume":"303","author":"C Ijichi","year":"2003","unstructured":"Ijichi, C., Matsumura, T., Tsuji, T. & Eto, Y. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun 303, 59\u201364 (2003).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep42710_CR47","doi-asserted-by":"crossref","first-page":"G1292","DOI":"10.1152\/ajpgi.00510.2003","volume":"288","author":"S Nishitani","year":"2005","unstructured":"Nishitani, S., Takehana, K., Fujitani, S. & Sonaka, I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 288, G1292\u20131300 (2005).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"BFsrep42710_CR48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmet.2007.08.003","volume":"6","author":"P She","year":"2007","unstructured":"She, P. et al. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 6, 181\u2013194 (2007).","journal-title":"Cell Metab"},{"key":"BFsrep42710_CR49","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00018-007-7076-0","volume":"64","author":"S Lahiri","year":"2007","unstructured":"Lahiri, S. & Futerman, A. H. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 64, 2270\u20132284 (2007).","journal-title":"Cell Mol Life Sci"},{"key":"BFsrep42710_CR50","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2353\/ajpath.2010.091257","volume":"177","author":"A Moles","year":"2010","unstructured":"Moles, A. et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 177, 1214\u20131224 (2010).","journal-title":"Am J Pathol"},{"key":"BFsrep42710_CR51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hep.21285","volume":"44","author":"L Llacuna","year":"2006","unstructured":"Llacuna, L., Mari, M., Garcia-Ruiz, C., Fernandez-Checa, J. C. & Morales, A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 44, 561\u2013572 (2006).","journal-title":"Hepatology"},{"key":"BFsrep42710_CR52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2174\/187152012800228689","volume":"12","author":"A Morales","year":"2012","unstructured":"Morales, A., Mari, M., Garcia-Ruiz, C., Colell, A. & Fernandez-Checa, J. C. Hepatocarcinogenesis and ceramide\/cholesterol metabolism. Anticancer Agents Med Chem 12, 364\u2013375 (2012).","journal-title":"Anticancer Agents Med Chem"},{"key":"BFsrep42710_CR53","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/gut.2010.216671","volume":"60","author":"HR Tagaram","year":"2011","unstructured":"Tagaram, H. R. et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 60, 695\u2013701 (2011).","journal-title":"Gut"},{"key":"BFsrep42710_CR54","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1128\/JVI.02530-07","volume":"82","author":"H Aizaki","year":"2008","unstructured":"Aizaki, H. et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 82, 5715\u20135724 (2008).","journal-title":"J Virol"},{"key":"BFsrep42710_CR55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2006.05.085","volume":"346","author":"T Umehara","year":"2006","unstructured":"Umehara, T. et al. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 346, 67\u201373 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep42710_CR56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jmv.21970","volume":"83","author":"K Tatematsu","year":"2011","unstructured":"Tatematsu, K., Tanaka, Y., Sugiyama, M., Sudoh, M. & Mizokami, M. Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. J Med Virol 83, 587\u2013593 (2011).","journal-title":"J Med Virol"},{"key":"BFsrep42710_CR57","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0092-8674(92)90553-O","volume":"71","author":"S Schutze","year":"1992","unstructured":"Schutze, S. et al. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced \u201cacidic\u201d sphingomyelin breakdown. Cell 71, 765\u2013776 (1992).","journal-title":"Cell"},{"key":"BFsrep42710_CR58","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0092-8674(94)90275-5","volume":"78","author":"K Wiegmann","year":"1994","unstructured":"Wiegmann, K., Schutze, S., Machleidt, T., Witte, D. & Kronke, M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78, 1005\u20131015 (1994).","journal-title":"Cell"},{"key":"BFsrep42710_CR59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","volume":"27","author":"M Mari","year":"2007","unstructured":"Mari, M. & Fernandez-Checa, J. C. Sphingolipid signalling and liver diseases. Liver Int 27, 440\u2013450 (2007).","journal-title":"Liver Int"},{"key":"BFsrep42710_CR60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.bcp.2012.08.006","volume":"84","author":"XX Wu","year":"2012","unstructured":"Wu, X. X. et al. Rebuilding the balance of STAT1 and STAT3 signalings by fusaruside, a cerebroside compound, for the treatment of T-cell-mediated fulminant hepatitis in mice. Biochem Pharmacol 84, 1164\u20131173 (2012).","journal-title":"Biochem Pharmacol"},{"key":"BFsrep42710_CR61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(97)70235-X","volume":"112","author":"A Bertoletti","year":"1997","unstructured":"Bertoletti, A. et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 112, 193\u2013199 (1997).","journal-title":"Gastroenterology"},{"key":"BFsrep42710_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940200546X","volume":"4","author":"S Malagarie-Cazenave","year":"2002","unstructured":"Malagarie-Cazenave, S. et al. Sphingolipid signalling: molecular basis and role in TNF-alpha-induced cell death. Expert Rev Mol Med 4, 1\u201315 (2002).","journal-title":"Expert Rev Mol Med"},{"key":"BFsrep42710_CR63","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/ATVBAHA.108.168682","volume":"28","author":"TK Hailemariam","year":"2008","unstructured":"Hailemariam, T. K. et al. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 28, 1519\u20131526 (2008).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep42710_CR64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2015.01.020","volume":"33","author":"SJ Zheng","year":"2015","unstructured":"Zheng, S. J. et al. Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. Int J Infect Dis 33, 149\u2013155 (2015).","journal-title":"Int J Infect Dis"},{"key":"BFsrep42710_CR65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbalip.2012.07.022","volume":"1831","author":"S Schwalm","year":"2013","unstructured":"Schwalm, S., Pfeilschifter, J. & Huwiler, A. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta 1831, 239\u2013250 (2013).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep42710_CR66","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jhep.2010.08.028","volume":"54","author":"C Li","year":"2011","unstructured":"Li, C. et al. Sphingosine 1-phosphate (S1P)\/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol 54, 1205\u20131213 (2011).","journal-title":"J Hepatol"},{"key":"BFsrep42710_CR67","unstructured":"Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B in 2010. Chinese Journal of experimental and clinical infectious diseases 5, 79\u2013100 (2011)."},{"key":"BFsrep42710_CR68","unstructured":"Ministry of Health of the People\u2019s Republic of China. Updated standards for the diagnosis and treatment of primary liver cancer. Zhonghua Gan Zang Bing Za Zhi 20, 419\u2013426 (2012)."},{"key":"BFsrep42710_CR69","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath, P. S. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464\u2013470 (2001).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42710","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T20:06:53Z","timestamp":1671826013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,12]]}},"alternative-id":["BFsrep42710"],"URL":"https:\/\/doi.org\/10.1038\/srep42710","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]},"assertion":[{"value":"26 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42710"}}